The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Serenoa repens for benign prostatic hyperplasia
Open accessAbstract
BACKGROUND: Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate, which can lead to obstructive and irritative lower urinary tract symptoms (LUTS). The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH is common. The extract of the berry of the American saw palmetto, or dwarf palm plant, Serenoa repens (SR), which is also known by its botanical name of Sabal serrulatum, is one of several phytotherapeutic agents available for the treatment of BPH. OBJECTIVES: This systematic review aimed to assess the effects and harms of Serenoa repens in the treatment of men with LUTS consistent with BPH. SEARCH METHODS: We searched for trials in general and in specialized databases, including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE®, EMBASE, CINAHL®, Web of Science, SCOPUS, BIOSIS Previews®, LILACS, ClinicalTrials.gov, Controlled-Trials.com, World Health Organization (WHO), and Google Scholar. We also handsearched systematic reviews, references, and clinical practice guidelines. There were no language restrictions. SELECTION CRITERIA: Trials were eligible if they randomized men with symptomatic BPH to receive preparations of SR (alone or in combination) for at least four weeks in comparison with placebo or other interventions, and included clinical outcomes, such as urologic symptom scales, symptoms, and urodynamic measurements. Eligibility was assessed by at least two independent observers (JT, RM). DATA COLLECTION AND ANALYSIS: One review author (JT) extracted Information on patients, interventions, and outcomes which was then checked by another review author (RM). The main outcome measure for comparing the effectiveness of SR with active or inert controls was change in urologic symptom-scale scores, with validated scores taking precedence over non validated ones. Secondary outcomes included changes in nocturia and urodynamic measures. The main outcome measure for harms was the number of men reporting side effects. MAIN RESULTS: In a meta-analysis of two high quality long-term trials (n = 582), Serenoa repens therapy was not superior to placebo in reducing LUTS based on the AUA (mean difference (MD) 0.25 points, 95% confidence interval (CI) -0.58 to 1.07). A 72 week trial with high quality evidence, using the American Urological Association Symptom Score Index, reported that SR was not superior to placebo at double and triple doses. In the same trial the proportions of clinical responders (≥ three-point improvement) were nearly identical (42.6% and 44.2% for SR and placebo, respectively), and not significant (RR 0.96, 95% CI 0.76 to 1.22).This update, which did not change our previous conclusions, included two new trials with 444 additional men, an 8.5% (5666/5222) increase from our 2009 updated review, and a 28.8% (1988/1544) increase for our main comparison, SR monotherapy versus placebo control (17 trials). Overall, 5666 men were assessed from 32 randomized, controlled trials, with trial lengths from four to 72 weeks. Twenty-seven trials were double blinded and treatment allocation concealment was adequate in 14.In a trial of high quality evidence (N = 369), versus placebo, SR did not significantly decrease nightly urination on the AUA Nocturia scale (range zero to five) at 72 weeks follow-up (one-sided P = 0.19).The three high quality, moderate-to-long term trials found peak urine flow was not improved with Serenoa repens compared with placebo (MD 0.40 mL/s, 95% CI -0.30 to 1.09).Comparing prostate size (mean change from baseline), one high quality 12-month trial (N = 225) reported no significant difference between SR and placebo (MD -1.22 cc, 95% CI -3.91 to 1.47). AUTHORS' CONCLUSIONS: Serenoa repens, at double and triple doses, did not improve urinary flow measures or prostate size in men with lower urinary tract symptoms consistent with BPH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Cited by
Interactions Between Herbal Medicines and Prescribed Drugs: An Updated Systematic Review
Izzo, A. A., & Ernst, E. (2009) · Drugs · doi:10.2165/11317010-000000000-00000 · Cited by 801
Interactions Between Herbal Medicines and Prescribed Drugs: A Systematic Review
Izzo, A. A., & Ernst, E. (2001) · Drugs · doi:10.2165/00003495-200161150-00002 · Cited by 714
Izzo, A. A., Hoon‐Kim, S., Radhakrishnan, R., & Williamson, E. M. (2016) · Phytotherapy Research · doi:10.1002/ptr.5591 · Cited by 532
Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents
Sparreboom, A., Cox, M. C., Acharya, M. R., & Figg, W. D. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.182 · Cited by 473
Ernst, E. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-1-200201010-00010 · Cited by 461
Metadata
- Authors
- Tacklind, J., MacDonald, R., Rutks, I., Stanke, J. U., & Wilt, T. J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2009-04-15
- Volume
- 12
- Issue
- 2
- Pages
- CD001423-CD001423
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2153435899
- Cited by
- 240
- References
- 1
- Type
- reference entry
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serenoa repens for benign prostatic hyperplasia. https://app.cochat.ai/papers/10.1002/14651858.cd001423.pub2
- The paper
- Tacklind, J., MacDonald, R., Rutks, I., Stanke, J. U., & Wilt, T. J. (2009). Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd001423.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.